Via: NeuroNews
Route 92 Medical has announced the publication of initial results from the SUMMIT NZ clinical trial—a single-arm, multicentre, prospective trial evaluating its proprietary Monopoint operating platform.
Results from the first 45 patients demonstrated that the Monopoint platform yielded an 80% first-pass effect with primary use of the HiPoint 88 (0.088-inch internal diameter [ID]) catheter, which is a super-bore catheter designed to consistently reach the proximal middle cerebral artery (MCA). The Route 92 HiPoint 88 aspiration catheter successfully reached the proximal MCA (M1 segment) in 100% of the cases attempted, as per a company press release. These results have been published online in the Journal of NeuroInterventional Surgery.
“The Monopoint operating platform with HiPoint 88 catheters delivered a step change in first-pass efficacy in the SUMMIT NZ trial, signalling clear potential for improved patient outcomes given the importance of clearing thrombus to save time and save brain,” said James Caldwell (Auckland City Hospital, Auckland, New Zealand), the paper’s first author. “The platform is designed to improve catheter deliverability, offering the advantage of greater simplicity for the operating physician to efficiently perform thrombectomy for patients.”
Read More: https://neuronewsinternational.com/route-92-publishes-data-demonstrating-80-first-pass-effect-with-novel-thrombectomy-system/
RSS Feed
